Contact Information: Contacts: Rachel Levine Director Corporate Development & Communications Cleveland BioLabs, Inc. T: (646) 284-9439 E: rlevine@hfgcg.com
Cleveland BioLabs to Present at 19th Annual Piper Jaffray Health Care Conference
| Source: Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwire - November 15, 2007) - Cleveland BioLabs, Inc. (NASDAQ : CBLI ) today
announced that the Company is scheduled to present at the 19th Annual Piper
Jaffray Global Health Care Conference, on November 27-29, in New York City.
Dr. Michael Fonstein, Chief Executive Officer and President of Cleveland
BioLabs, will give a presentation on November 27, at 8:00 a.m. EST on the
Company's technology platform and lead products. The presentation will be
followed by a question and answer session and a live webcast may be
accessed at the Company's website, www.cbiolabs.com or at
http://www.piperjaffray.com/conferences. A replay of the presentation will
be archived for 30 days after the conference, at the same locations.
Cleveland BioLabs management will be available for meetings in New York on
November 27-28.
The Company's platform technology utilizes proprietary knowledge regarding
regulated cell death (apoptosis) to develop drugs which either temporarily
suppress cell death in select tissues to protect from acute stresses such
as radiation and ischemia (a condition in which blood flow, and thus
oxygen, is restricted to a part of the body), or induce cell death to treat
cancer.
Cleveland BioLabs currently has two lead compounds in late stages of
development. Curaxin CBLC102 is an orally administered small molecule
designed to kill tumor cells by simultaneously targeting two key regulators
of apoptosis. The Company has an ongoing Phase II trial with CBLC102 in
hormone refractory prostate cancer and will begin additional Phase II
trials in Renal Cell Carcinoma and multiple cancer types in the coming
months.
The Company's other lead compound, Protectan CBLB502, is a modified protein
of a microbe that temporarily protects cells from regulated cell death.
CBLB502 is the first compound of its kind to provide protection from both
gastrointestinal and hematopoietic (bone marrow/blood production)
radiation-induced damage.
Cleveland BioLabs submitted CBLB502 to the Department of Defense (DoD) in
response to a Request for Proposal (RFP) for medical radiation
countermeasures to treat gastrointestinal effects of acute radiation
syndrome. The RFP award would provide funding for development of the
countermeasure through FDA approval, leading to purchase of up to 500,000
doses, thereafter. The Company expects the DoD to make its decision on the
RFP this year.
CBLB502 is undergoing an accelerated development program under the FDA
two-animal rule, which requires demonstrations of efficacy in two animal
species and only safety in humans. The Company recently announced the
completion of Good Manufacturing Practices compliant (cGMP) manufacturing
of Protectan CBLB502 and plans to submit an Investigational New Drug (IND)
application to the FDA for a human safety study this year.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries about programmed cell death to treat
cancer and protect normal tissues from exposure to radiation and other
stresses. The Company has strategic partnerships with the Cleveland
Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed
Forces Research Radiobiology Institute. To learn more about Cleveland
BioLabs Inc., please visit the company's website at
http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. Our actual
results could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Some of the
factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in our periodic filings with the Securities and
Exchange Commission.